Canadian Journal Addiction Medicine - Canadian Harm Reduction ...
Canadian Journal Addiction Medicine - Canadian Harm Reduction ...
Canadian Journal Addiction Medicine - Canadian Harm Reduction ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table III: Reported naloxone use among 50 Edmonton area opioid users after 1 year of a pilot project<br />
Variable N (%)<br />
Recipient:<br />
A friend<br />
An acquaintance<br />
My partner<br />
A stranger<br />
Myself<br />
Location of Use:<br />
Private Residence<br />
Other<br />
On the street<br />
Drugs involved in the overdose *<br />
Opioid<br />
Cocaine/Crack<br />
Other drugs<br />
Alcohol<br />
*<br />
Totals N>9 due to more than one drug being involved in some overdoses.<br />
3 (33%)<br />
3 (33%)<br />
1 (11%)<br />
1 (11%)<br />
1 (11%)<br />
4 (44%)<br />
3 (33%)<br />
2 (22%)<br />
9 (100%)<br />
4 (44%)<br />
2 (22%)<br />
1 (11%)<br />
Table IV: Comparison of Participant Drug Use Before and After Naloxone Training<br />
Drug Baseline (N) * Exit (N) p-value<br />
Opioids:<br />
Heroin<br />
Morphine<br />
Hydromorphone<br />
Codeine<br />
Oxycodone<br />
Propoxyphene<br />
Methadone<br />
Stimulants:<br />
Crack<br />
Cocaine<br />
Methamphetamines<br />
Others:<br />
Benzodiazepines<br />
Marijuana<br />
Alcohol<br />
3<br />
13<br />
8<br />
9<br />
12<br />
2<br />
7<br />
14<br />
8<br />
5<br />
13<br />
7<br />
8<br />
*<br />
N represents the number of people who reported regular use during the last six months.<br />
3<br />
7<br />
4<br />
8<br />
7<br />
1<br />
8<br />
12<br />
3<br />
1<br />
8<br />
8<br />
9<br />
1.0<br />
0.05<br />
0.26<br />
1.0<br />
0.12<br />
0.60<br />
1.0<br />
0.13<br />
0.60<br />
0.17<br />
0.11<br />
1.0<br />
1.0<br />
References<br />
November 2012<br />
Patra J, Taylor B, Rehm JT, Baliunas D, Popova S. Substanceattributable<br />
morbidity and mortality changes to Canada’s<br />
epidemiological profile: measurable differences over a ten-year<br />
period. Can J Public Health 2007;98(3):228-34.<br />
Rehm J, Gnam W, Popova S, Baliunas D, Brochu S, Fischer B, et al.<br />
The costs of alcohol, illegal drugs, and tobacco in Canada, 2002.<br />
J Stud Alcohol Drugs 2007;68(6):886-95.<br />
Popova S, Rehm J, Fischer B. An overview of illegal opioid use<br />
and health services utilization in Canada. Public Health<br />
2006;120(4):320-8.<br />
Fischer B, Rehm J, Goldman B, Popova S. Non-medical use of<br />
prescription opioids and public health in Canada: an urgent call<br />
for research and interventions development. Can J Public Health<br />
2008;99(3):182-4.<br />
Currie CL, Schopflocher DP, Wild TC. Prevalence and correlates of<br />
12-month prescription drug misuse in Alberta. Can J Psychiatry<br />
2011;56(1):27-34.<br />
Hsu W, Rao RB, Nelson LS. Naloxone hazards overstated. J Toxicol<br />
Clin Toxicol 1997;35(2):215-7.<br />
Sporer KA, Kral KH. Prescription naloxone: a novel approach to heroin<br />
overdose prevention. Ann Emerg Med 2007;49(2):172-7.<br />
Baca CT, Grant KJ. Take-home naloxone to reduce heroin death.<br />
<strong>Addiction</strong> 2005;100(12):1823-31.<br />
8